LGVN (Longeveron) Moat Score: 4/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LGVN Longeveron Inc LGVN
45 GF Score
Price $0.61
GF Value $0.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Longeveron Moat Score?

Longeveron LGVN +1.40% 45 Moat Score is 4 as of Jul. 20, 2026. GuruFocus rates LGVN with a GF Score™ of 45/100 and a GF Value™ of $0.38 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,396 Biotechnology companies, Longeveron ranks better than 88.83% on this metric.

Longeveron has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Longeveron has Narrow Moat: Longeveron Inc has discernible advantages in the biotech sector with some valuable intellectual property and R&D capabilities. However, it lacks strong brand strength, significant customer switching costs, and durable cost advantages, limiting its moat to a modest level.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Longeveron might have Narrow Moat - Discernible but modest moat.

Longeveron  (NAS:LGVN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Longeveron Moat Score Related Terms

LGVN vs MRKR, PLUR, VYNE: Moat Score Comparison

For the Biotechnology subindustry, Longeveron's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longeveron Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's Moat Score distribution charts can be found below:

* The bar in red indicates where Longeveron's Moat Score falls into.


LGVN
45GF Score
Longeveron Inc LGVN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Longeveron (LGVN) has a Moat Score of 4 as of Jul. 20, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Longeveron ranks #156 out of 1396 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Longeveron's Moat Score too high?
Longeveron's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Longeveron's value of 4 is 100% above this industry median. Based on the distribution chart, Longeveron ranks #156 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Longeveron has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Longeveron's Moat Score compare to MRKR and PLUR?
According to the Biotechnology industry distribution chart, Longeveron ranks #156 out of 1396 companies for Moat Score. This places Longeveron in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Longeveron's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Longeveron's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longeveron's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longeveron stock overvalued right now?
Based on GuruFocus' analysis, Longeveron (LGVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.38, compared to a current price of $0.61 — trading 60.8% above its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Longeveron's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Longeveron (LGVN), the current Moat Score is 4 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Longeveron (LGVN) Overvalued in 2026?

Based on GuruFocus' analysis, Longeveron stock appears to be overvalued. The current stock price of $0.61 is trading 60.8% above its estimated GF Value™ of $0.38. GuruFocus considers Longeveron to be Significantly Overvalued.

Key valuation signals for LGVN:

  • Moat Score: 4
  • GF Value™: $0.38 vs. price of $0.61 (60.8% above fair value)
  • GF Score™: 45/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#156 of 1396)

No single metric tells the full story. See the LGVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Longeveron Business Description

Address 1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
45GF Score

Get the complete analysis for LGVN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price
$0.38
GF Value